Awaiting development: Guidance and quality standards
Showing 11 to 17 of 17
| Title | Type |
|---|---|
| Sigvotatug vedotin for Non-small-cell lung cancer [ID6718] | Technology appraisal guidance |
| Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443] | Technology appraisal guidance |
| Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064] | Technology appraisal guidance |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708] | Technology appraisal guidance |
| Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603] | Technology appraisal guidance |
| Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651] | Technology appraisal guidance |
| Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573] | Technology appraisal guidance |